Literature DB >> 6172141

Cellular distribution of monoclonal antibody in human tumours after i.v. administration.

V Moshakis, R A McIlhinney, A M Neville.   

Abstract

Immune-suppressed mice carrying xenografts of several different types of human germ-cell tumours were injected with a radiolabelled monoclonal antibody (LICR LON/HT13) raised against membrane components of a human germ-cell tumour (HX39). Subsequent assessment of radioactivity in excised organs and tumours showed a selective accretion of antibody in the tumour. Quantitative autoradiography supported the results of radiolocalization observed in vivo in different tumours, and also showed that the antibody localized to viable tumour cells and in close association with their cell membrane. The vascular architecture of tumours was found to be an important factor governing antibody distribution. No localization occurred with radiolabelled normal mouse IgG.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 6172141      PMCID： PMC2010824          DOI： 10.1038/bjc.1981.251

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  10 in total

1.  In vivo localisation of radiolabelled antibodies to carcinoembryonic antigen in human colon carcinoma grafted into nude mice.

Authors:  J P Mach; S Carrel; C Merenda; B Sordat; J C Cerottini
Journal:  Nature       Date:  1974-04-19       Impact factor: 49.962

2.  Localization of human GW-39 tumors in hamsters by radiolabeled heterospecific antibody to carcinoembryonic antigen.

Authors:  F J Primus; R H Wang; D M Goldenberg; H J Hansen
Journal:  Cancer Res       Date:  1973-11       Impact factor: 12.701

3.  The localization of radioantibodies in human brain tumors. II. Radioautography.

Authors:  M S Mahaley; J L Mahaley; E D Day
Journal:  Cancer Res       Date:  1965-07       Impact factor: 12.701

4.  Localization of radioiodinated antibody to alpha-fetoprotein in hepatoma transplanted in rats and a case report of alpha-fetoprotein antibody treatment of a hepatoma patient.

Authors:  T Koji; N Ishii; T Munehisa; Y Kusumoto; S Nakamura; A Tamenishi; A Hara; K Kobayashi; Y Tsukada; S Nishi; H Hirai
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

5.  Localization of 131I-labeled antibodies in human renal cell carcinomas and in a mouse hepatoma and correlation with tumor detection by photoscanning.

Authors:  T Ghose; S T Norvell; J Aquino; P Belitsky; J Tai; A Guclu; A H Blair
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

6.  Tumor location detected with radioactively labeled monoclonal antibody and external scintigraphy.

Authors:  B Ballou; G Levine; T R Hakala; D Solter
Journal:  Science       Date:  1979-11-16       Impact factor: 47.728

7.  Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning.

Authors:  D M Goldenberg; F DeLand; E Kim; S Bennett; F J Primus; J R van Nagell; N Estes; P DeSimone; P Rayburn
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

8.  Tumor localization of radiolabeled antibodies against carcinoembryonic antigen in patients with carcinoma: a critical evaluation.

Authors:  J P Mach; S Carrel; M Forni; J Ritschard; A Donath; P Alberto
Journal:  N Engl J Med       Date:  1980-07-03       Impact factor: 91.245

9.  Localization of human breast-carcinoma xenografts using antibodies to carcinoembryonic antigen.

Authors:  V Moshakis; M J Bailey; M G Ormerod; J H Westwood; A M Neville
Journal:  Br J Cancer       Date:  1981-05       Impact factor: 7.640

10.  Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies.

Authors:  V Moshakis; R A McIlhinney; D Raghavan; A M Neville
Journal:  Br J Cancer       Date:  1981-07       Impact factor: 7.640
  10 in total
  8 in total

1.  Radioimmunodetection of cancer: problems and potential.

Authors:  E M Rankin; J G McVie
Journal:  Br Med J (Clin Res Ed)       Date:  1983-11-12

2.  Use of monoclonal antibodies and liposomes to improve drug delivery. Present status and future implications.

Authors:  G Gregoriadis
Journal:  Drugs       Date:  1982-10       Impact factor: 9.546

3.  Human parathyroid antigen: characterization and localization with monoclonal antibodies.

Authors:  W G Cance; S A Wells; W G Dilley; M J Welch; F L Otsuka; J M Davie
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

Review 4.  Antibody-mediated targeting in the treatment and diagnosis of cancer: an overview.

Authors:  C H Ford; A G Casson
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts.

Authors:  F E Yang; R S Brown; K F Koral; A C Clavo; G A Jackson; R L Wahl
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

Review 6.  Antitumor monoclonal antibodies for radioimmunodetection of tumors and drug targeting.

Authors:  R W Baldwin; M V Pimm
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

7.  Monoclonal antibodies in the treatment of cancer: preliminary observations and future prospects.

Authors:  R K Oldham; A C Morgan; C S Woodhouse; R W Schroff; P G Abrams; K A Foon
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

8.  The site of binding of anti-CEA antibodies to tumour CEA in vivo: an immunocytochemical and autoradiographic approach.

Authors:  V Moshakis; M G Ormerod; J H Westwood; S Imrie; A M Neville
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.